Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Compound, derived from a rare South American plant, stops the growth of human breast cancer cells

They started with a bare room and an idea. Now, after five years of painstaking, sophisticated tests, scientists at the University of Virginia Health System have discovered that a compound, derived from a rare South American plant, stops the growth of human breast cancer cells in laboratory cultures.

1 Feb 2005

Why some men develop aggressive prostate cancer that becomes resistant to hormone-withdrawal therapy

Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.

26 Jan 2005

Researchers to test new leukemia drug

Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.

12 Jan 2005

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Researchers have discovered that specific cancer-causing genes associated with leukemias can transform mature white blood cells into leukemic cells that have all the properties of stem cells.

21 Dec 2004

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

30 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.

8 Nov 2004

Obesity could more than double an older woman's risk of acute myelogenous leukemia

A study from the University of Minnesota Cancer Center indicates that overweight and obesity could more than double an older woman's risk of acute myelogenous leukemia (AML), an often fatal cancer of the bone marrow and blood.

8 Nov 2004

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Maxim Pharmaceuticals has announced that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene(TM) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA earlier this year.

2 Nov 2004

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

21 Sep 2004

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Cytogen Corporation today announced the presentation of new data relating to its lead therapeutic product Quadramet (samarium Sm-153 lexidronam injection) during the 36th Congress of the International Society of Pediatric Oncology (SIOP).

20 Sep 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004

Guidelines for determining the best possible time to receive bone marrow transplants

Bone marrow transplant, the only cure for patients with myelodysplastic syndrome (MDS), is a life-saving procedure but carries with it many risks and potential side effects.

2 Jul 2004

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Compared to the snapshot views of the immune system from tumor biopsies or blood assays, this whole body imaging allows scientists to track how the immune response changes, and the tumor or infection responds, throughout the different phases of immune response and over long periods of time.

15 Jun 2004

Smoking a lot more harmful than previously thought

The U.S. Surgeon General has released a new comprehensive report on smoking and health, revealing for the first time that smoking causes diseases in nearly every organ of the body. Published 40 years after the surgeon general's first report on smoking -- which concluded that smoking was a definite cause of three serious diseases -- this newest report finds that cigarette smoking is conclusively linked to diseases such as leukemia, cataracts, pneumonia and cancers of the cervix, kidney, pancreas and stomach.

30 May 2004

Smoking causes diseases in nearly every organ of the body

U.S. Surgeon General Richard H. Carmona today released a new comprehensive report on smoking and health, revealing for the first time that smoking causes diseases in nearly every organ of the body.

27 May 2004

Myeloid Leukemia News and Research

Compound, derived from a rare South American plant, stops the growth of human breast cancer cells

Why some men develop aggressive prostate cancer that becomes resistant to hormone-withdrawal therapy

Researchers to test new leukemia drug

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

A new treatment for patients with chronic myeloid leukemia

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Obesity could more than double an older woman's risk of acute myelogenous leukemia

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

New compound that is designed to overcome Gleevec resistance

Guidelines for determining the best possible time to receive bone marrow transplants

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Smoking a lot more harmful than previously thought

Smoking causes diseases in nearly every organ of the body

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News